From Molecular to Nanotechnology Strategies for Delivery of Neurotrophins: Emphasis on Brain-Derived Neurotrophic Factor (BDNF)
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Neurodegenerative diseases represent a major public health problem, but beneficial clinical treatment with neurotrophic factors has not been established yet. The therapeutic use of neurotrophins has been restrained by their instability and rapid degradation in biological medium. A variety of strategies has been proposed for the administration of these leading therapeutic candidates, which are essential for the development, survival and function of human neurons. In this review, we describe the existing approaches for delivery of brain-derived neurotrophic factor (BDNF), which is the most abundant neurotrophin in the mammalian central nervous system (CNS). Biomimetic peptides of BDNF have emerged as a promising therapy against neurodegenerative disorders. Polymer-based carriers have provided sustained neurotrophin delivery, whereas lipid-based particles have contributed also to potentiation of the BDNF action. Nanotechnology offers new possibilities for the design of vehicles for neuroprotection and neuroregeneration. Recent developments in nanoscale carriers for encapsulation and transport of BDNF are highlighted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Neurotrophin-regulated signalling pathways
Reichardt, L. F. (2006) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2006.1894 · Cited by 2,195
Brain-Derived Neurotrophic Factor and Neuropsychiatric Disorders
Autry, A. E., & Monteggia, L. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005108 · Cited by 1,390 · cited 4×
“Several studies have shown the involvement of BDNF in the pathogenesis of neurodegenerative diseases and psychiatric disorders, like depression and schizophrenia [4,6,15,16,27,37,50].”
BackgroundInfluentialBrain foods: The effects of nutrients on brain function.
Gómez-Pinilla, F. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2421 · Cited by 1,372 · cited 2×
“These neuroprotective molecules exert considerable control over the life and death pathways in cells [10–31].”
BackgroundDirect brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
New insights into BDNF function in depression and anxiety
Martinowich, K., Manji, H., & Lu, B. (2007) · Nature Neuroscience · doi:10.1038/nn1971 · Cited by 1,221 · cited 1×
“Several studies have shown the involvement of BDNF in the pathogenesis of neurodegenerative diseases and psychiatric disorders, like depression and schizophrenia [4,6,15,16,27,37,50].”
BackgroundA phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050
Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034 · cited 3×
“Gene transfer via lentivirus or adenovirus followed by protein expression BDNF Alzheimer’s disease mice; rats; monkeys; clinical trials broad neuroprotective effects [5,32]”
BackgroundBrain-derived neurotrophic factor in neurodegenerative diseases
Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947
Dwivedi, Y., Rizavi, H. S., Conley, R. R., Roberts, R. C., Tamminga, C. A., & Pandey, G. N. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.8.804 · Cited by 875 · cited 2×
“neurotrophin-based drug delivery system should be evaluated by its capacity to modulate the BDNF levels and activate receptor TrkB signaling [35–87].”
BackgroundMurer, M. G., Yan, Q., & Raisman-Vozari, R. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00014-9 · Cited by 874 · cited 4×
“It is a key molecular target in the development of drugs against neurological disorders [3–6,19,23,31,32,88–108].”
BackgroundInfluentialPotential therapeutic uses of BDNF in neurological and psychiatric disorders
Nagahara, A. H., & Tuszynski, M. H. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3366 · Cited by 867 · cited 3×
“Indeed, increasing of the BDNF levels has contributed to modifying the neurological disease progressions by diminishing neuronal death [1,5,63].”
BackgroundCastrén, E., & Rantamäki, T. (2010) · Developmental Neurobiology · doi:10.1002/dneu.20758 · Cited by 864
Saarelainen, T., Hendolin, P., Lucas, G., Koponen, E., Sairanen, M., MacDonald, E., Agerman, K., Haapasalo, A., Nawa, H., Aloyz, R., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-01-00349.2003 · Cited by 800
Postsynaptic BDNF‐TrkB signaling in synapse maturation, plasticity, and disease
Yoshii, A., & Constantine‐Paton, M. (2010) · Developmental Neurobiology · doi:10.1002/dneu.20765 · Cited by 744
Scharfman, H., Goodman, J., Macleod, A., Phani, S., Antonelli, C., & Croll, S. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.11.016 · Cited by 719 · cited 2×
“The rational design of neurotrophin-based therapeutics and delivery systems [53,63,149–229] requires a good understanding of the structures of the neurotrophic proteins and their receptors, as well as of their interactions and mechanisms of action at the molecular level.”
BackgroundEssential role of brain-derived neurotrophic factor in adult hippocampal function
Monteggia, L. M., Barrot, M., Powell, C. M., Berton, O., Galanis, V., Gemelli, T., Meuth, S., Nagy, A., Greene, R. W., & Nestler, E. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402141101 · Cited by 685 · cited 3×
“These neuroprotective molecules exert considerable control over the life and death pathways in cells [10–31].”
BackgroundDelivery of therapeutic agents to the central nervous system: the problems and the possibilities
Begley, D. J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.08.001 · Cited by 679 · cited 2×
“The majority of known nanoparticulate systems for drug delivery and targeting to the CNS [230,233–241] have not been exploited for neurotrophin delivery yet.”
BackgroundA Genetic Variant BDNF Polymorphism Alters Extinction Learning in Both Mouse and Human
Soliman, F., Glatt, C. E., Bath, K. G., Levita, L., Jones, R. M., Pattwell, S. S., Jing, D., Tottenham, N., Amso, D., Somerville, L. H., et al. (2010) · Science · doi:10.1126/science.1181886 · Cited by 585 · cited 2×
“neurotrophin-based drug delivery system should be evaluated by its capacity to modulate the BDNF levels and activate receptor TrkB signaling [35–87].”
BackgroundYang, J., Siao, C.-J., Nagappan, G., Marinic, T., Jing, D., McGrath, K., Chen, Z.-Y., Mark, W., Tessarollo, L., Lee, F. S., et al. (2009) · Nature Neuroscience · doi:10.1038/nn.2244 · Cited by 449
Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents
Massa, S. M., Yang, T., Xie, Y., Shi, J., Bilgen, M., Joyce, J. N., Nehama, D., Rajadas, J., & Longo, F. M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41356 · Cited by 406 · cited 2×
“Prodrugs of non-peptide neurotrophin mimetics non-peptide mimetics of BDNF Psychiatric disorders Mice reduced depression- and anxiety-related behaviors; blood-brain barrier penetration [213,215]”
BackgroundBrain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity.
Cowansage, K., LeDoux, J., & Monfils, M.-H. (2010) · Current Molecular Pharmacology · doi:10.2174/1874467211003010012 · Cited by 372 · cited 2×
“neurotrophin-based drug delivery system should be evaluated by its capacity to modulate the BDNF levels and activate receptor TrkB signaling [35–87].”
BackgroundBrain‐Derived Neurotrophic Factor in Neuronal Survival and Behavior‐Related Plasticity
LIPSKY, R. H., & MARINI, A. M. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1403.009 · Cited by 361 · cited 3×
“It plays a role in the mechanisms of alcohol and drug addiction [25].”
BackgroundCentral administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects
Hoshaw, B. A., Malberg, J. E., & Lucki, I. (2005) · Brain Research · doi:10.1016/j.brainres.2005.01.007 · Cited by 348
Schäbitz, W.-R., Schwab, S., Spranger, M., & Hacke, W. (1997) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199705000-00003 · Cited by 322
Gomez, N., & Schmidt, C. E. (2007) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.31047 · Cited by 306
Rantamäki, T., Hendolin, P., Kankaanpää, A., Mijatovic, J., Piepponen, P., Domenici, E., Chao, M. V., Männistö, P. T., & Castrén, E. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301345 · Cited by 305
Levivier, M., Przedborski, S., Bencsics, C., & Kang, U. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-12-07810.1995 · Cited by 274 · cited 1×
“Transplants of genetically-engineered fibroblasts expressing the protein BDNF; NGF; NT-3 Parkinson’s disease; Spinal cord injury rats increased nigral dopaminergic neuronal survival responsiveness to axonal regeneration [103,127, 137]”
BackgroundFrim, D. M., Uhler, T. A., Galpern, W. R., Beal, M. F., Breakefield, X. O., & Isacson, O. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.5104 · Cited by 269 · cited 1×
“Transplants of genetically-engineered fibroblasts expressing the protein BDNF; NGF; NT-3 Parkinson’s disease; Spinal cord injury rats increased nigral dopaminergic neuronal survival responsiveness to axonal regeneration [103,127, 137]”
BackgroundPreparation and brain delivery property of biodegradable polymersomes conjugated with ox26
Pang, Z., Lu, W., Gao, H., Hu, K., Chen, J., Zhang, C., Gao, X., Jiang, X., & Zhu, C. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.03.007 · Cited by 264
Richardson, R. T., Thompson, B., Moulton, S., Newbold, C., Lum, M. G., Cameron, A., Wallace, G., Kapsa, R., Clark, G., & O’Leary, S. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.09.008 · Cited by 251
Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles
Kurakhmaeva, K. B., Djindjikhashvili, I. A., Petrov, V. E., Balabanyan, V. U., Voronina, T. A., Trofimov, S. S., Kreuter, J., Gelperina, S., Begley, D., & Alyautdin, R. N. (2009) · Journal of Drug Targeting · doi:10.1080/10611860903112842 · Cited by 221
Slevin, J. T., Gash, D. M., Smith, C. D., Gerhardt, G. A., Kryscio, R., Chebrolu, H., Walton, A., Wagner, R., & Young, A. B. (2007) · Journal of neurosurgery · doi:10.3171/jns.2007.106.4.614 · Cited by 173
Effective GDNF brain delivery using microspheres—A promising strategy for Parkinson's disease
Garbayo, E., Montero-Menei, C. N., Ansorena, E., Lanciego, J. L., Aymerich, M. S., & Blanco-Prieto, M. J. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.12.010 · Cited by 150 · cited 5×
“Controlled local release of GDNF from biodegradable PLGA microspheres has been realized with rats subjected to brain stereotaxy for local intracranial microspheres implantation [90,98,104–106,115,116].”
BackgroundMethodInfluentialAdvances in small molecules promoting neurotrophic function
PRICE, R., MILNE, S., SHARKEY, J., & MATSUOKA, N. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.03.005 · Cited by 148
Bariohay, B., Roux, J., Tardivel, C., Trouslard, J., Jean, A., & Lebrun, B. (2009) · Endocrinology · doi:10.1210/en.2008-1184 · Cited by 95
Therapeutics, imaging and toxicity of nanomaterials in the central nervous system.
Nunes, A., Al-Jamal, K. T., & Kostarelos, K. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.026 · Cited by 75 · cited 1×
“The majority of known nanoparticulate systems for drug delivery and targeting to the CNS [230,233–241] have not been exploited for neurotrophin delivery yet.”
BackgroundSirianni, R. W., Olausson, P., Chiu, A. S., Taylor, J. R., & Saltzman, W. M. (2010) · Brain Research · doi:10.1016/j.brainres.2010.01.041 · Cited by 51
Jollivet, C., Aubert-Pouessel, A., Clavreul, A., Venier-Julienne, M.-C., Montero-Menei, C. N., Benoit, J.-P., & Menei, P. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2003.11.051 · Cited by 43
Cited by
Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation
Lima Giacobbo, B., Doorduin, J., Klein, H. C., Dierckx, R. A. J. O., Bromberg, E., & de Vries, E. F. J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1283-6 · Cited by 750
BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases
Lu, B., Nagappan, G., Guan, X., Nathan, P. J., & Wren, P. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3505 · Cited by 743
BDNF as a Promising Therapeutic Agent in Parkinson’s Disease
Palasz, E., Wysocka, A., Gasiorowska, A., Chalimoniuk, M., Niewiadomski, W., & Niewiadomska, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031170 · Cited by 504
“The fact that clinical trials have met with little success may be explained taking into account that successful delivery of therapeutic molecules should evade (i) rapid protein elimination from the cerebral circulation owing to enzymatic degradation, (ii) capture by the reticuloendothelial system, (iii) macromolecular…”
BackgroundTejeda, G., & Díaz-Guerra, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020268 · Cited by 126
Vitaliano, G. D., Kim, J. K., Kaufman, M. J., Adam, C. W., Zeballos, G., Shanmugavadivu, A., Subburaju, S., McLaughlin, J. P., Lukas, S. E., & Vitaliano, F. (2022) · Communications Biology · doi:10.1038/s42003-022-03177-3 · Cited by 48
Metadata
- Authors
- Géral, C., Angelova, A., & Lesieur, S.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2013-02-08
- Volume
- 5
- Issue
- 1
- Pages
- 127-167
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W1988394046
- Cited by
- 123
- References
- 41
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.